


# Jornada de innovación en cáncer urotelial.

Hot Topics and Daily Challenges in Urothelial Cancer

Dirigido a profesionales  
Formato presencial y online

3 de octubre 2024  
12:00 horas

Hospital Universitario  
HM Sanchinarro  
Auditorio Reina Sofía  
C/ de Oña, 10, 28050 Madrid



Organiza

Director del curso

**fundaciónhm**  
investigación

Dra. Elena Sevillano Fernández  
M.D. PhD Unidad de Tumores Urológicos, Ginecológicos y piel  
HM Hospitales

Coordinador del curso

Dr. Jesús García-Donas  
M.D PhD M.D. Unidad de Tumores Urológicos, Ginecológicos y piel

**hm hospitales**

## Composición de la mesa

### Ponentes:

Dr. Joaquim Bellmunt  
Dr. Jesús García-Donas.  
Dr. Guillermo de Velasco  
Dr. Félix Guerrero  
Dr. Alfonso Gómez de Liaño  
Dr. Pablo Gajate  
Dra. Elena Sevillano

### Moderadores:

Dra. Elena Sevillano  
Dr. Jesús García-Donas

## Programa

### 12.00-12.10h Introducción

#### EARLY STAGE

#### 12.10-12.30h Non Muscle Invasive

- BGC unresponsiveness and alternatives to radical cystectomy?
- Best options for patients after BCG

#### 12.30-13.30h Muscle Invasive Bladder Cancer

- Neoadjuvant immune checkpoint inhibitors vs neoadjuvant cisplatin-based chemotherapy for MIBC?
- Bladder sparing options vs trimodality therapy or radical cystectomy
- Adjuvant treatment options in high risk patients of bladder cancer and upper tract urothelial cancer
- New combinations options and biomarkers of response
- Does variant histologies change your recommendations?

#### 13.30h-14.30h Advanced Disease

- First line current strategies. Are we evolving towards a platinum-free future in urothelial cancer?
- Second line therapy: Choosing wisely
- Molecularly guided therapies for metastatic urothelial cancer
- How FGFR status impacts treatment decisions and sequencing consideration?
- Antibody-Drug Conjugates: new winning horse?
- Where are we with treating HER2 genomic alterations?
- Novel biomarkers associated with treatment outcomes
- What is the role of artificial intelligence in screening and diagnostic of bladder cancer?
- What is new and on the horizon?

Patrocinan

AstraZeneca

astellas

MERCK

Johnson&Johnson

Bristol Myers Squibb™

**hm**  
**hm hospitales**  
Somos tu Salud